Advertisement
Research Article| Volume 30, ISSUE 3, P180-184, December 2002

Download started.

Ok

Inhibitory effects of oral prednisolone and fexofenadine on skin responses by prick tests with histamine and compound 48/80

      Abstract

      The prick test is a useful skin test for diagnosing immediate hypersensitivity response. Sometimes it is necessary to perform prick tests on patients who have already received antihistamines or corticosteroids. It is, however, occasionally uncertain whether the results of prick tests are reliable. In this study, the inhibitory effects of prednisolone (10 mg/day) and fexofenadine (120 mg/day) on the response to prick tests induced with histamine and compound 48/80 were examined. During a 7-day-continual drug administration, prick tests were performed 8 h after drug administration. The inhibitory effects of fexofenadine on both the histamine- and compound 48/80-induced skin responses were exhibited on the 1st day and persisted from 24 to 36 h after the final administration. The histamine-induced wheal responses were not inhibited by prednisolone, while the compound 48/80-induced flare and wheal responses were significantly inhibited on the 5th day of drug administration. These responses returned to the baseline level 24 h after the last drug administration. Thus, the results of skin tests performed during administration of antihistamines and corticosteroids should be carefully interpreted.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Dermatological Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mondroe E.W.
        Urticaria.
        Int. J. Dermatol. 1981; 20: 32-41
        • Furue M.
        • Terao H.
        • Koga T.
        Effects of cetirizine and epinastine on the skin response to histamine iontophoresis.
        J. Dermatol. Sci. 2001; 25: 59-63
        • Borici-Mazi R.
        • Kouridakis S.
        • Kontou-Fili K.
        Cutaneous responses to substance P and calcitonin gene-related peptide in chronic urticaria: the effect of cetirizine and dimethindene.
        Allergy. 1999; 54: 46-56
        • Van Neste D.
        • Coussement C.
        • Ghys L.
        • Rihoux J.P.
        Agonist–antagonist interactions in the skin: comparison of effects of loratadine and cetirizine on skin vascular responses to prick tests with histamine and substance P.
        J. Dermatol. Sci. 1992; 4: 172-179
        • Cappugi P.
        • Tsampau D.
        • Lotti T.
        Substance P provokes cutaneous erythema and edema through a histamine-independent pathway.
        Int. J. Dermatol. 1992; 31: 206-209
        • Coulson I.H.
        • Holden C.A.
        Cutaneous reactions to substance P and histamine in atopic dermatitis.
        Br. J. Dermatol. 1990; 122: 343-349
        • Olson R.
        • Karpink M.H.
        • Shelanski S.
        • Atkins P.C.
        • Zweiman B.
        Skin reactivity to codeine and histamine during prolonged corticosteroid therapy.
        J. Allergy Clin. Immunol. 1990; 86: 153-159
        • Dreborg S.
        Skin test used in type 1 allergy testing, Position paper.
        Allergy. 1989; 44: 22-30
        • Fadel R.
        • Ramboer I.
        • Chatterjee N.
        • Rihoux J.P.
        • Derde M.P.
        Cetirizine inhibits bradykinin-induced cutaneous wheal and flare in atopic and healthy subjects.
        Allergy. 2000; 55: 888-891
        • Petersen L.J.
        • Church M.K.
        • Skov P.S.
        Histamine is released in the weal but not the flare following challenge of human skin in vivo: A microdialysis study.
        Clin. Exp. Allergy. 1997; 27: 284-295
        • Lopez-Campos C.
        • Rincon-Castaneda C.B.
        • Cano-Rios P.
        • Martinez-Ordaz V.A.
        • Velasco-Rodriguez V.M.
        Is the histamine skin test inhibited by prednisone?.
        Arch. Med. Res. 1998; 29: 63-65
        • Makham A.
        • Wagstaff A.J.
        Fexofenadine.
        Drugs. 1998; 55: 269-274
        • Flower R.J.
        • Blackwell G.J.
        Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin biosynthesis.
        Nature. 1979; 278: 456-459
        • Goppelt-Struebe M.
        • Wolter D.
        • Resch K.
        Glucocorticoids inhibit prostaglandin synthesis not only at the level cyclo-oxygenase/PGE isomerase.
        Br. J. Pharmacol. 1989; 98: 1287-1295
        • Oyanagui Y.
        Anti-inflammatory effects of polyamines in serotonin and carragreenan paw edemata-possible mechanism to increase vascular permeability inhibitory protein level which is regulated by glucocorticoids and superoxide radical.
        Agents Actions. 1984; 14: 228-237
        • Inagaki N.
        • Miura T.
        • Nagai H.
        • Ono Y.
        • Koda A.
        Inhibition of vascular permeability increase in mice.
        Int. Arch. Allergy Appl. Immunol. 1988; 87: 254-259
        • Sugio K.
        • Ohuchi K.
        • Sugata M.
        • Tsurufuji S.
        Suppression by dexamethasone of vascular permeability responses induced with leukotrienes C and D in the rat skin.
        Prostaglandins. 1981; 21: 649-653
        • Svensjö E.
        • Roempke K.
        Time-dependent inhibition of bradykinin- and histamine-induced microvasucular permeability increase by local glucocorticoid treatment.
        Prog. Respir. Res. 1985; 19: 173-180
        • Björk J.
        • Goldschmidt T.
        • Smedegard G.
        • Arfors K.E.
        Methylprednisolone acts at the endtherial cell level reducing inflammatory responses.
        Acta Physiol. Scand. 1985; 123: 221-223
        • Oyanagui Y.
        • Suzuki S.
        Vasoregulin, a glucocorticoid-inducible vascular permability inhibitory protein.
        Agent Actions. 1985; 17: 270-277
        • Di Rosa M.
        • Calignano A.
        • Carnuccio R.
        • Ialenti A.
        • Sautebin L.
        Multiple control of inflammation by glucocorticoids.
        Agents Actions. 1985; 17: 284-289